Virax Biolabs Group Limited (VRAX)
Last updated: 2026-10-24 20:41:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Virax Biolabs Group Limited (VRAX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.23, with a market capitalization of $984.28K and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.15 to $21.75. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$984.28K | |
$1.24 | |
$7,250.00 | |
$1.15 | |
$1.24 | |
33.73K | |
399.22K | |
-- | |
$21.75 | |
$1.15 | |
-- | |
-- |
Virax Biolabs Group Limited (VRAX) Latest Closing Stock Price
Virax Biolabs Group Limited (VRAX) last closed at $1.24 as of 2026-10-23 23:31:00, unchanged from the previous close of $1.24.
During the latest regular trading session, VRAX traded between $1.15 and $7,250.00, with a volume of 33.73K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Virax Biolabs Group Limited (VRAX) 7-Day Stock Price Change
Over the past seven days, Virax Biolabs Group Limited (VRAX) moved from $1.62 to $1.23, representing a decline of 24.39% ($0.40).
The stock traded between $1.15 and $1.76 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 28.28 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
VRAX 52-Week Price Position
Position in Range: 0.4%
VRAX is currently trading at $1.23, placing it 0.4% of the way from its 52-week low of $1.15 to its 52-week high of $21.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Virax Biolabs Group Limited (VRAX)?
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Virax Biolabs Group Limited Information
| Employees | 26 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Virax Biolabs Group Limited (VRAX) Stock on MEXC
Eligible investors can buy real shares of Virax Biolabs Group Limited (VRAX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Virax Biolabs Group Limited (VRAX) stock price today?
2.Is VRAX stock going up or down today?
3.What is VRAX pre-market price?
4.What is VRAX after-hours price?
5.Is VRAX stock trading now?
6.Where does VRAX sit relative to its 52-week high and low?
7.What sector is Virax Biolabs Group Limited in?
8.What is Virax Biolabs Group Limited's market capitalization and where is it listed?
9.How is VRAX valued in terms of P/E ratio and EPS?
10.Does Virax Biolabs Group Limited pay a dividend?
Explore More US Stocks
Search Stocks
VRAX Stock Calculator
Estimate the value between VRAX shares and USD.
VRAX Shares to USD
1.00 VRAX shares = 1.225 USD
Calculations are estimates based on the latest available price and are for reference only.


